CENTOGENE NV (CNTG) 0.7175 -0.08 (-9.74%)
0.7175 -0.08 (-9.74%)
NL0014040206 - Common Stock
CENTOGENE to Participate in Upcoming Conferences in December
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for...
CENTOGENE to Participate in Upcoming Conferences in December
CNTG stock spikes as H.C. Wainwright initiates Buy with over 200% upside (NASDAQ:CNTG)
Shares of German nano-cap life sciences company Centogene N.V. (CNTG) rallied in the morning hours Wednesday after H.C
CENTOGENE Announces Changes to Supervisory Board, Including Appointment of Mary Sheahan
Adding significant financial expertise with an impressive track record in value creation
CENTOGENE Announces Changes to Supervisory Board, Including Appointment of Mary Sheahan
Adding significant financial expertise with an impressive track record in value creation...
CENTOGENE to Participate in Upcoming Conferences in November
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for...
CENTOGENE to Participate in Upcoming Conferences in November
CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network
Company’s launch of Biodata Network offers new portfolio of data-driven solutionsCollaboration with BC Platforms increases access to data-driven genomic...
CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network
CENTOGENE to Participate in Upcoming Partnering Conferences in October
CENTOGENE to Participate in Upcoming Partnering Conferences in October
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential...
CENTOGENE to Present at Upcoming Investor & Partnering Conferences in September
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential...
CENTOGENE Reports First Quarter 2022 Financial Results
On Track for FY 2022 Guidance Q1 2022 revenue rises 3% to €10.3 million Completed phase out of COVID-19 Business segment in Q1 2022Positioning Pharma and...
CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential...
CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer
Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFO...
CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease
Working together on the world’s first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18...
CENTOGENE’s CentoCloud® Is Now CE-Marked as One of the Only Decentralized SaaS Platforms Compliant With European IVD Regulatory Framework
CE-marked clinical decision support platform enables laboratories to provide best-in-class diagnostics of genetic diseases...